Aadi Bioscience Appoints New CMO, Elects Director
Ticker: WHWK · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1422142
Sentiment: neutral
Topics: executive-changes, board-of-directors, compensation
Related Tickers: AADI
TL;DR
AADI shakes up leadership: new CMO, new board member, and exec comp details filed.
AI Summary
Aadi Bioscience, Inc. announced on September 15, 2024, the appointment of Dr. Rajul Patel as Chief Medical Officer and the election of Ms. Sarah Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, including Dr. Patel, as part of its ongoing business operations.
Why It Matters
These executive changes and board appointments can signal shifts in leadership strategy and governance, potentially impacting the company's future direction and operational focus.
Risk Assessment
Risk Level: medium — Changes in key executive roles and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Aadi Bioscience, Inc. (company) — Registrant
- Dr. Rajul Patel (person) — Appointed Chief Medical Officer
- Ms. Sarah Kelly (person) — Elected to Board of Directors
- September 15, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Rajul Patel has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Sarah Kelly has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 15, 2024.
What items are covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
What is the state of incorporation for Aadi Bioscience, Inc.?
Aadi Bioscience, Inc. is incorporated in Delaware.
Filing Stats: 740 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-09-19 16:13:59
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share AADI The Nasdaq Stock Mar
- $390,000 — tion Bonus Letter, a retention bonus of $390,000 to Dr. Lennon and $220,000 to Mr. Giaco
- $220,000 — ion bonus of $390,000 to Dr. Lennon and $220,000 to Mr. Giacobello, in each case if such
Filing Documents
- d880684d8k.htm (8-K) — 25KB
- d880684dex101.htm (EX-10.1) — 25KB
- 0001193125-24-222116.txt ( ) — 178KB
- aadi-20240915.xsd (EX-101.SCH) — 3KB
- aadi-20240915_lab.xml (EX-101.LAB) — 18KB
- aadi-20240915_pre.xml (EX-101.PRE) — 11KB
- d880684d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of Retention Bonus Letter 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 19, 2024 /s/ Scott Giacobello Scott Giacobello Chief Financial Officer